Full Name
Prof Ashok Venkitaraman
Designation
Director, Cancer Science Institute of Singapore
Distinguished Professor of Medicine, YLL School of Medicine, NUS
Programme Director, A*STAR, Singapore
Distinguished Professor of Medicine, YLL School of Medicine, NUS
Programme Director, A*STAR, Singapore
Bio
Professor Ashok Venkitaraman is the Director of the Cancer Science Institute of Singapore, and a Distinguished Professor of Medicine at NUS Yong Loo Lin School of Medicine, a member of the National University Health System (NUHS). He holds a joint appointment at the Agency for Science, Technology and Research (A*STAR).
Prof Venkitaraman’s research has contributed fundamentally to our understanding of how cancer is suppressed by genes that maintain the integrity of DNA in the human genome. His laboratory is recognized for the discovery that mutations in the breast and ovarian cancer gene, BRCA2, provoke genome instability leading to carcinogenesis. Prof Venkitaraman now seeks to achieve a deeper understanding of the steps that underlie carcinogenesis, in order to find new strategies to intercept cancer development well before the disease reaches an advanced and hard-to- treat stage. He has developed new technologies to target previously ‘undruggable’ targets, and is a serial biotech entrepreneur, most recently as a founder of PhoreMost Ltd.
Prof. Venkitaraman has been elected a Fellow of the Academy of Medical Sciences, London, and as a member of EMBO.
Prof Venkitaraman’s research has contributed fundamentally to our understanding of how cancer is suppressed by genes that maintain the integrity of DNA in the human genome. His laboratory is recognized for the discovery that mutations in the breast and ovarian cancer gene, BRCA2, provoke genome instability leading to carcinogenesis. Prof Venkitaraman now seeks to achieve a deeper understanding of the steps that underlie carcinogenesis, in order to find new strategies to intercept cancer development well before the disease reaches an advanced and hard-to- treat stage. He has developed new technologies to target previously ‘undruggable’ targets, and is a serial biotech entrepreneur, most recently as a founder of PhoreMost Ltd.
Prof. Venkitaraman has been elected a Fellow of the Academy of Medical Sciences, London, and as a member of EMBO.
Topic
Towards early intervention in cancer: Can we improve outcomes?
Abstract
Cancer is a major cause of death worldwide. As yet unexploited opportunities for early intervention – through detection, risk stratification & therapeutic or preventive interception - occur across the course of the disease. There is persuasive clinical evidence that early intervention will save lives, improve patient outcomes, and reduce healthcare costs. This talk will discuss how our rapidly increasing understanding of the fundamental mechanisms underlying carcinogenesis is opening new opportunities for early intervention, through the lens of cancer predisposition triggered by germline mutations in the breast cancer gene BRCA2.
